Adial Begin Period Cash Flow vs Cash And Cash Equivalents Changes Analysis

ADIL Stock

USD 1.09 0.03 2.83%

Adial Pharmaceuticals financial indicator trend analysis is way more than just evaluating Adial Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adial Pharmaceuticals is a good investment. Please check the relationship between Adial Pharmaceuticals Begin Period Cash Flow and its Cash And Cash Equivalents Changes accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.

Begin Period Cash Flow vs Cash And Cash Equivalents Changes

Begin Period Cash Flow vs Cash And Cash Equivalents Changes Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adial Pharmaceuticals Begin Period Cash Flow account and Cash And Cash Equivalents Changes. At this time, the significance of the direction appears to have pay attention.

The correlation between Adial Pharmaceuticals' Begin Period Cash Flow and Cash And Cash Equivalents Changes is -0.9. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Cash And Cash Equivalents Changes in the same time period over historical financial statements of Adial Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Adial Pharmaceuticals' Begin Period Cash Flow and Cash And Cash Equivalents Changes is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Adial Pharmaceuticals are associated (or correlated) with its Cash And Cash Equivalents Changes. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Cash Equivalents Changes has no effect on the direction of Begin Period Cash Flow i.e., Adial Pharmaceuticals' Begin Period Cash Flow and Cash And Cash Equivalents Changes go up and down completely randomly.

Correlation Coefficient

-0.9

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Cash And Cash Equivalents Changes

Most indicators from Adial Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adial Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.At this time, Adial Pharmaceuticals' Enterprise Value Over EBITDA is quite stable compared to the past year. Enterprise Value Multiple is expected to rise to 0.02 this year, although the value of Selling General Administrative will most likely fall to about 5.1 M.

	2024	2025 (projected)
Depreciation And Amortization	648.6	616.17
Interest Income	122.2K	128.3K

Depreciation And Amortization Interest Income

Adial Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Capital Surpluse	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Short Long Term Debt Total	Net Receivables	Short Long Term Debt	Other Stockholder Equity
Total Assets		0.76	0.7	0.94	0.91	-0.97	-0.72	0.58	0.98	0.57	0.47	0.83	0.98	-0.84	0.58	0.86	0.84	0.66	0.98	-0.14	0.47	-0.84	-0.23	-0.22	0.83	0.8
Other Current Liab	0.76		0.94	0.51	0.45	-0.72	-0.7	0.52	0.74	0.56	0.35	0.6	0.74	-0.61	0.49	0.72	0.71	0.96	0.72	-0.09	0.85	-0.61	-0.16	-0.14	0.59	0.69
Total Current Liabilities	0.7	0.94		0.42	0.37	-0.63	-0.62	0.69	0.68	0.51	0.32	0.68	0.68	-0.7	0.45	0.64	0.7	0.99	0.66	0.21	0.78	-0.7	0.15	-0.14	0.67	0.63
Total Stockholder Equity	0.94	0.51	0.42		0.98	-0.93	-0.62	0.46	0.93	0.49	0.46	0.76	0.93	-0.76	0.54	0.79	0.75	0.37	0.94	-0.23	0.2	-0.76	-0.32	-0.23	0.77	0.73
Net Tangible Assets	0.91	0.45	0.37	0.98		-0.93	-0.49	0.48	0.93	0.34	0.31	0.71	0.93	-0.71	0.4	0.71	0.72	0.32	0.94	-0.25	0.16	-0.71	-0.29	-0.17	0.71	0.6
Net Debt	-0.97	-0.72	-0.63	-0.93	-0.93		0.56	-0.56	-0.99	-0.38	-0.27	-0.73	-0.99	0.75	-0.39	-0.75	-0.78	-0.61	-0.99	0.24	-0.45	0.75	0.25	0.09	-0.74	-0.64
Retained Earnings	-0.72	-0.7	-0.62	-0.62	-0.49	0.56		-0.32	-0.6	-0.94	-0.85	-0.69	-0.6	0.66	-0.93	-0.92	-0.75	-0.6	-0.6	0.05	-0.47	0.66	0.34	0.49	-0.63	-0.96
Accounts Payable	0.58	0.52	0.69	0.46	0.48	-0.56	-0.32		0.59	0.24	0.18	0.73	0.59	-0.75	0.24	0.49	0.73	0.58	0.6	0.29	0.24	-0.75	0.33	-0.11	0.71	0.39
Cash	0.98	0.74	0.68	0.93	0.93	-0.99	-0.6	0.59		0.45	0.34	0.79	1.0	-0.8	0.46	0.79	0.79	0.65	1.0	-0.15	0.46	-0.8	-0.19	-0.18	0.78	0.69
Non Current Assets Total	0.57	0.56	0.51	0.49	0.34	-0.38	-0.94	0.24	0.45		0.97	0.66	0.45	-0.6	0.99	0.85	0.56	0.48	0.44	0.1	0.27	-0.6	-0.22	-0.71	0.55	0.88
Non Currrent Assets Other	0.47	0.35	0.32	0.46	0.31	-0.27	-0.85	0.18	0.34	0.97		0.61	0.34	-0.54	0.97	0.79	0.45	0.27	0.34	0.13	0.02	-0.54	-0.2	-0.77	0.48	0.8
Other Assets	0.83	0.6	0.68	0.76	0.71	-0.73	-0.69	0.73	0.79	0.66	0.61		0.79	-0.99	0.68	0.75	0.75	0.6	0.79	0.36	0.29	-0.99	0.22	-0.41	0.96	0.77
Cash And Short Term Investments	0.98	0.74	0.68	0.93	0.93	-0.99	-0.6	0.59	1.0	0.45	0.34	0.79		-0.8	0.46	0.79	0.79	0.65	1.0	-0.15	0.46	-0.8	-0.19	-0.18	0.78	0.69
Common Stock Total Equity	-0.84	-0.61	-0.7	-0.76	-0.71	0.75	0.66	-0.75	-0.8	-0.6	-0.54	-0.99	-0.8		-0.62	-0.72	-0.76	-0.62	-0.81	-0.35	-0.32	1.0	-0.24	0.31	-0.97	-0.75
Common Stock Shares Outstanding	0.58	0.49	0.45	0.54	0.4	-0.39	-0.93	0.24	0.46	0.99	0.97	0.68	0.46	-0.62		0.86	0.59	0.41	0.46	0.12	0.22	-0.62	-0.22	-0.73	0.57	0.88
Capital Surpluse	0.86	0.72	0.64	0.79	0.71	-0.75	-0.92	0.49	0.79	0.85	0.79	0.75	0.79	-0.72	0.86		0.85	0.6	0.79	-0.16	0.38	-0.72	-0.4	-0.54	0.67	0.91
Other Current Assets	0.84	0.71	0.7	0.75	0.72	-0.78	-0.75	0.73	0.79	0.56	0.45	0.75	0.79	-0.76	0.59	0.85		0.64	0.81	-0.12	0.51	-0.76	-0.26	-0.2	0.75	0.8
Total Liab	0.66	0.96	0.99	0.37	0.32	-0.61	-0.6	0.58	0.65	0.48	0.27	0.6	0.65	-0.62	0.41	0.6	0.64		0.63	0.14	0.86	-0.62	0.08	-0.1	0.59	0.59
Total Current Assets	0.98	0.72	0.66	0.94	0.94	-0.99	-0.6	0.6	1.0	0.44	0.34	0.79	1.0	-0.81	0.46	0.79	0.81	0.63		-0.15	0.44	-0.81	-0.2	-0.18	0.79	0.68
Short Term Debt	-0.14	-0.09	0.21	-0.23	-0.25	0.24	0.05	0.29	-0.15	0.1	0.13	0.36	-0.15	-0.35	0.12	-0.16	-0.12	0.14	-0.15		-0.07	-0.35	0.88	-0.2	0.32	-0.02
Intangible Assets	0.47	0.85	0.78	0.2	0.16	-0.45	-0.47	0.24	0.46	0.27	0.02	0.29	0.46	-0.32	0.22	0.38	0.51	0.86	0.44	-0.07		-0.32	-0.11	0.14	0.33	0.45
Common Stock	-0.84	-0.61	-0.7	-0.76	-0.71	0.75	0.66	-0.75	-0.8	-0.6	-0.54	-0.99	-0.8	1.0	-0.62	-0.72	-0.76	-0.62	-0.81	-0.35	-0.32		-0.24	0.31	-0.97	-0.75
Short Long Term Debt Total	-0.23	-0.16	0.15	-0.32	-0.29	0.25	0.34	0.33	-0.19	-0.22	-0.2	0.22	-0.19	-0.24	-0.22	-0.4	-0.26	0.08	-0.2	0.88	-0.11	-0.24		0.06	0.21	-0.29
Net Receivables	-0.22	-0.14	-0.14	-0.23	-0.17	0.09	0.49	-0.11	-0.18	-0.71	-0.77	-0.41	-0.18	0.31	-0.73	-0.54	-0.2	-0.1	-0.18	-0.2	0.14	0.31	0.06		-0.18	-0.38
Short Long Term Debt	0.83	0.59	0.67	0.77	0.71	-0.74	-0.63	0.71	0.78	0.55	0.48	0.96	0.78	-0.97	0.57	0.67	0.75	0.59	0.79	0.32	0.33	-0.97	0.21	-0.18		0.77
Other Stockholder Equity	0.8	0.69	0.63	0.73	0.6	-0.64	-0.96	0.39	0.69	0.88	0.8	0.77	0.69	-0.75	0.88	0.91	0.8	0.59	0.68	-0.02	0.45	-0.75	-0.29	-0.38	0.77

Click cells to compare fundamentals

Adial Pharmaceuticals Account Relationship Matchups

Adial Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	5.5M	7.5M	5.7M	4.7M	5.4M	4.4M
Other Current Liab	856.6K	2.4M	1.4M	525.7K	604.5K	761.2K
Total Current Liabilities	1.5M	2.7M	1.8M	653.1K	751.0K	1.1M
Total Stockholder Equity	4.0M	3.5M	3.3M	4.1M	4.7M	3.1M
Net Tangible Assets	4.4M	7.1M	4.0M	2.8M	3.2M	2.7M
Net Debt	(4.4M)	(5.8M)	(3.8M)	(2.8M)	(2.5M)	(2.7M)
Retained Earnings	(31.5M)	(50.9M)	(63.7M)	(68.8M)	(61.9M)	(58.8M)
Accounts Payable	648.7K	286.2K	276.4K	127.4K	146.5K	267.2K
Cash	4.4M	6.1M	4.0M	2.8M	3.3M	3.4M
Non Current Assets Total	355.6K	1.0M	952.9K	1.5M	1.8M	1.9M
Non Currrent Assets Other	0.0	350K	455K	1.5M	1.8M	1.9M
Cash And Short Term Investments	4.4M	6.1M	4.0M	2.8M	3.3M	3.4M
Common Stock Shares Outstanding	498.5K	743.5K	1.1M	1.4M	1.6M	1.7M
Liabilities And Stockholders Equity	5.5M	7.5M	5.7M	4.7M	5.4M	4.4M
Other Current Assets	734.7K	399.4K	778.1K	371.6K	427.3K	370.5K
Total Liab	1.5M	4.0M	2.5M	653.1K	751.0K	1.3M
Total Current Assets	5.1M	6.5M	4.8M	3.2M	3.7M	3.9M
Intangible Assets	5.6K	460.0K	459.5K	3.9K	4.5K	4.3K
Common Stock	14.4K	20.9K	26.7K	1.7K	1.5K	1.4K
Non Current Liabilities Total	648.7K	1.2M	665.4K	437.0	502.55	477.42
Other Stockholder Equity	35.5M	54.4M	66.9M	72.9M	83.8M	43.0M
Net Invested Capital	7.1M	4.0M	3.5M	3.3M	3.8M	4.0M
Net Working Capital	7.1M	3.6M	3.7M	3.0M	3.4M	3.8M
Capital Stock	10.4K	14.4K	20.9K	26.7K	30.7K	17.4K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Adial Pharmaceuticals is a strong investment it is important to analyze Adial Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adial Pharmaceuticals' future performance. For an informed investment choice regarding Adial Stock, refer to the following important reports:

How To Invest In Adial

Details

Is Adial Stock a good investment?

Details

What is Adial Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.94)

Return On Assets

(1.04)

Return On Equity

(3.21)

The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Adial Begin Period Cash Flow vs Cash And Cash Equivalents Changes Analysis

Begin Period Cash Flow vs Cash And Cash Equivalents Changes

Begin Period Cash Flow vs Cash And Cash Equivalents Changes Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Cash And Cash Equivalents Changes

Adial Pharmaceuticals fundamental ratios Correlations

Adial Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Adial Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Total Liab	+ 0.99	Total Current Liabilities
Common Stock Shares Outstanding	+ 0.99	Non Current Assets Total

Common Stock	- 0.99	Other Assets
Common Stock Total Equity	- 0.99	Other Assets
Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Short Long Term Debt	- 0.97	Common Stock